NO20083968L - Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom - Google Patents

Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom

Info

Publication number
NO20083968L
NO20083968L NO20083968A NO20083968A NO20083968L NO 20083968 L NO20083968 L NO 20083968L NO 20083968 A NO20083968 A NO 20083968A NO 20083968 A NO20083968 A NO 20083968A NO 20083968 L NO20083968 L NO 20083968L
Authority
NO
Norway
Prior art keywords
prevent
receptor antagonists
adenosine receptor
hepatic disease
treat hepatic
Prior art date
Application number
NO20083968A
Other languages
English (en)
Norwegian (no)
Inventor
Dewan Zeng
Luiz Belardinelli
Hongyan Zhong
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20083968L publication Critical patent/NO20083968L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20083968A 2006-03-17 2008-09-17 Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom NO20083968L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20083968L true NO20083968L (no) 2008-12-15

Family

ID=38514256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083968A NO20083968L (no) 2006-03-17 2008-09-17 Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom

Country Status (14)

Country Link
US (4) US7795268B2 (enExample)
EP (1) EP1996201A2 (enExample)
JP (2) JP5250848B2 (enExample)
KR (1) KR101428113B1 (enExample)
CN (1) CN101405003B (enExample)
AU (1) AU2007227021B2 (enExample)
CA (2) CA2646333C (enExample)
IL (1) IL194158A0 (enExample)
MX (1) MX2008011828A (enExample)
NO (1) NO20083968L (enExample)
NZ (1) NZ571324A (enExample)
RU (1) RU2457842C2 (enExample)
WO (1) WO2007109547A2 (enExample)
ZA (1) ZA200807894B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
RU2357969C2 (ru) * 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
MX2007004373A (es) 2004-10-15 2007-08-08 Cv Therapeutics Inc Metodo para prevenir y tratar el remoldeo de las vias respiratorias e inflamacion pulmonar utilizando antagonistas de receptor adenosina a2b.
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
EP2301937A1 (en) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
CN101479290A (zh) * 2006-06-27 2009-07-08 比奥维特罗姆上市公司 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090208550A1 (en) * 2007-10-26 2009-08-20 Cronstein Bruce N Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3368064B1 (en) 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
KR102852334B1 (ko) 2016-02-10 2025-09-01 웨이크 포리스트 유니버시티 헬스 사이언시즈 간 섬유화의 모델 시스템 및 그의 제조 및 사용 방법
KR101709307B1 (ko) * 2016-10-31 2017-02-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
EP3634417B1 (en) * 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
EP3675856A4 (en) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING THE A2B ADENOSINE RECEPTOR AND A2A ADENOSINE RECEPTOR
CN112218867B (zh) 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
JP7394831B2 (ja) * 2018-07-27 2023-12-08 アーカス バイオサイエンシズ インコーポレイティド ピリドンａ２ｒアンタゴニスト
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
NZ532816A (en) 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2004086052A2 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP2301937A1 (en) 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Also Published As

Publication number Publication date
JP5250848B2 (ja) 2013-07-31
JP2009530413A (ja) 2009-08-27
CA2646333A1 (en) 2007-09-27
RU2008137279A (ru) 2010-03-27
EP1996201A2 (en) 2008-12-03
CA2849661A1 (en) 2007-09-27
US8609671B2 (en) 2013-12-17
AU2007227021B2 (en) 2012-12-20
IL194158A0 (en) 2009-08-03
US20140243358A1 (en) 2014-08-28
WO2007109547A2 (en) 2007-09-27
US8188099B2 (en) 2012-05-29
CN101405003A (zh) 2009-04-08
NZ571324A (en) 2011-07-29
US20120220608A1 (en) 2012-08-30
CA2646333C (en) 2014-06-17
US7795268B2 (en) 2010-09-14
AU2007227021A1 (en) 2007-09-27
CN101405003B (zh) 2011-05-11
JP2013049719A (ja) 2013-03-14
US20110184002A1 (en) 2011-07-28
RU2457842C2 (ru) 2012-08-10
MX2008011828A (es) 2008-09-29
ZA200807894B (en) 2009-05-27
WO2007109547A3 (en) 2007-11-29
KR20080107416A (ko) 2008-12-10
US20070219221A1 (en) 2007-09-20
KR101428113B1 (ko) 2014-08-07

Similar Documents

Publication Publication Date Title
NO20083968L (no) Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom
NO20072733L (no) Doseformer
WO2010034670A3 (en) Host cell kinases as targets for antiviral therapies against hcv infection
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
MX2020005345A (es) Un método para inhibir o reducir una infección viral por coronavirus.
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
EA200900297A1 (ru) Ингибиторы вируса гепатита с
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
WO2014089296A3 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007143607A3 (en) Method of treating atrophic vaginitis
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
NO20084411L (no) Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
BRPI0710682B8 (pt) combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
WO2008033754A3 (en) Xanthine derivatives in methods and compositions for the treatment of vascular depression
WO2008121461A3 (en) Vaccine for activating helper function of cd8+ tcells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application